EcoDrugPlus

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSBMUG00000006695
Gene Symbol: PTPRB
3 Cross references
268 Possible Orthologues:

Purine Nucleoside Phosphorylase

Ensembl ID : ENSBMUG00000006756
Gene Symbol: LOC102270686
2 Cross references
74 Possible Orthologues:

Purinergic Receptor P2x 3

Ensembl ID : ENSBMUG00000016620
Gene Symbol: P2RX3
3 Cross references
272 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSBMUG00000017559
Gene Symbol: P2RY1
3 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y12

Ensembl ID : ENSBMUG00000021583
Gene Symbol: P2RY12
3 Cross references
182 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSBMUG00000018978
Gene Symbol: P2RY2
3 Cross references
200 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSBMUG00000000632
Gene Symbol: P2RY4
3 Cross references
168 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSBMUG00000019022
Gene Symbol: P2RY6
3 Cross references
183 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSBMUG00000017028
Gene Symbol: RAMP1
1 Cross references
252 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSBMUG00000009980
Gene Symbol: RIPK1
3 Cross references
198 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-4

Ensembl ID : ENSBMUG00000021361
Gene Symbol: LOC102275229
2 Cross references
319 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSBMUG00000017805
Gene Symbol: RPTOR
3 Cross references
208 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).